Keyword: Pfizer

Chris Corsico left the CMO spot at Boehringer Ingelheim to fill a new role at GlaxoSmithKline: senior vice president of development.

The data suggest filgotinib is safe and as effective as JAK rivals including AbbVie’s upadacitinib, setting the stage for a four-way commercial scrap.

The early-stage alliance comes a week after Pfizer halted development of domagrozumab in DMD because of lackluster midphase data.

Allogene’s bustling first few months have continued with a $120 million private financing round to advance off-the-shelf CAR-T.

Hu-manity.co launched a global ledger where people can claim their healthcare data as a personal property right and then sell it to researchers.

SpringWorks Therapeutics named its first CEO and unveiled a partnership with BeiGene around a combination therapy for RAS-mutated cancers.

Arvinas has filed to raise up to $100 million in its IPO to get its lead assets through the IND stage and into phase 1.

Pfizer halted two phase 2 trials of its Duchenne muscular dystrophy drug domagrozumab after the main efficacy study failed its primary endpoint.

Pfizer’s ATTR drug tafamidis has hit the mark in a phase 3 trial, setting up regulatory filings and a challenge to rivals Alnylam and Ionis/Akcea.

uniQure has treated the first of around three patients due to enroll in its phase 2b dose-confirmation trial of hemophilia B gene therapy AMT-061.